- Home
- / Intellia Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Intellia Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$16.3
2024-10-28
Market Capitalization
$1.7 B
2024-10-28
Revenue
$67.7 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.4M | 43.1M | 58.0M | 33.1M | 52.1M | 36.3M | 57.9M | 67.7M | ||
| Gross profit | 30.4M | 43.1M | 58.0M | |||||||
| Gross profit margin, % | 100.0% | 100.0% | 100.0% | |||||||
| General and administrative expense | 16.8M | 28.0M | 32.2M | 41.1M | 44.2M | 71.1M | 90.3M | 116.5M | 125.8M | 119.8M |
| Operating expense total | 48.6M | 95.7M | 121.3M | 149.5M | 194.6M | 300.9M | 510.3M | 551.6M | 592.1M | 508.7M |
| EBIT | (32.2M) | (69.6M) | (90.9M) | (106.4M) | (136.6M) | (267.8M) | (458.2M) | (515.3M) | (534.3M) | (441.0M) |
| EBIT margin, % | -298.6% | -246.8% | -235.5% | -879.0% | -1420.5% | -923.1% | -651.7% | |||
| Investment income | 1.3M | (11.1M) | (15.6M) | |||||||
| Interest income | 525.0K | 2.0M | 5.5M | 6.8M | 2.4M | 1.3M | 8.5M | 49.8M | 47.8M | 29.2M |
| Pre tax profit | (31.6M) | (67.5M) | ||||||||
| Net Income | (31.6M) | (67.5M) | (85.3M) | (99.5M) | (134.2M) | (267.9M) | (474.2M) | (481.2M) | (519.0M) | (412.7M) |
| EPS | (6.2) | (5.4) | (5.2) | (3.8) |